Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Université de Lille · Université Toulouse III - Paul Sabatier · +22 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
457
total citations
- FWCI
- 54.33
- Percentile
- 100%
- References
- 37
Citations per year
Authors
24Topics & keywords
Topics
Keywords
- Medicine
- Pemetrexed
- Nivolumab
- Internal medicine
- Mesothelioma
- Neutropenia
- Pleural disease
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.